International Circulation: The HEAAL trial was presented today， from which we saw some interesting results. Obviously you are intimately involved with the trial so we would like to get you view on the results and impact of the trial. Can you give us a brief introduction?

《国际循环》：HEAAL试验结果于今天发表，从中可以看到一些有意义的结果。您也亲身参与了这项研究，因此我们很想知道您对这项研究的结果和影响有何看法？您能简要介绍一下么？

    Prof. Neaton：We were very happy， as you might imagine， with the results. They clearly show that higher doses of Losartin are more effect in preventing a broad range of clinical outcomes than the lower doses.  Importantly， as Dr. Konstam indicated in the presentation this morning， this may reflect the need for titrating doses of these drugs and ACE inhibitors are higher and are to give their maximal effects. This is the first trial with a dose comparison for this class of drugs， which we think will have an impact， above and beyond those data presented this morning， with future research.

    Neaton教授：我们对结果很满意。该结果表明，与小剂量相比，大剂量氯沙坦可以更有效的改善较大范围的临床结局。更重要的是，正如Konstam博士在今天早上的演讲中所指明的，这表明需要逐渐增加此类药物和ACE抑制剂的剂量以达到最大效应。这是此类药物剂量之间进行对比的首个临床试验，进一步的研究将会超越今天早上列举的这些数据。